This study, developed within the Innovative Medicines Initiative Joint Undertaking (IMI JU) project PRECISESADS framework, was undertook to functionally characterize the CD14+ and CD16+ monocyte subsets in RA patients, and analyze their involvement in the increased CV risk associated with RA Figure S1. This evidence concerns the gene CD14 and rheumatoid arthritis.